Trial Profile
A Phase II, Randomized, Double-Blind, Placebo Controlled, Multi-Center Study to Evaluate the Effects of LCI699 on Cortisol in Patients With Hypertension.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Osilodrostat (Primary)
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Novartis
- 01 Sep 2012 Results published in the Journal of Clinical Hypertension (Greenwich).
- 24 Feb 2011 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 25 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.